About AVT
Browse Articles
Authors
Customer Services

Short communication

Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina

Moira Vignoles, Graciela Barboni, María R Agosti, Jorge Quarleri, Mariel K García, Silvia González Ayala, Horacio Salomón

Corresponding author name: Horacio Salomón
Corresponding author e-mail: hsalomon@fmed.uba.ar

Citation: Antiviral Therapy 2009; 14:1175-1181
doi: 10.3851/IMP1461

Date accepted: 12 July 2009
Date published online: 15 December 2009

Abstract

Background: The aim of this study was to describe the frequency of minority populations of viruses carrying mutations K103N and M184V in drug-naive HIV type-1 (HIV-1)-infected children, and to further evaluate their effect on the selection of drug-resistant viruses within highly active antiretroviral therapy (HAART).

Methods: Newly diagnosed vertically HIV-1-infected children were evaluated. The HIV-1 pol gene was sequenced for subtyping and antiretroviral drug resistance analysis. Standard genotypic sequencing and sequence-selective real-time PCR (SPCR) to quantify minority viral populations were used.

Results: From December 2004 to July 2006, we included 35 children who were studied at baseline and during their first HAART regimen (follow-up median time 29.4 months). Of them, 82.9% were infected with intersubtype B/F recombinant variants. At baseline, all children had a drug-susceptible viral population that was studied by bulk sequencing. SPCR showed that 4 children had between 2–10% of M184V, 11 had <0.7%, 18 had no detectable mutation and 2 could not be amplified. No K103N minority populations were found. Once under HAART, children who had 2–10% of M184V at baseline further selected it in percentages >20% in less time than those with -0.1–0.6% or without minority populations (P=0.01).

Conclusions: It was shown that having 2–10% of M184V at baseline enhanced its selection in high percentages in a short time after HAART initiation. Further research regarding the presence of minority quasispecies before initiation of HAART in large paediatric populations should be undertaken to evaluate their clinical effect during HAART.

<< BACK

Copyright © Nucleus Group 2010. Part of the Nucleus Group of Companies.
Design and Technology by the Nucleus Group
Company registration No. 321 0712 (England & Wales). Registered Office address: 36 St Mary at Hill, London, EC3R 8DU.